Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report

doi:10.5306/wjco.v16.i3.101766

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1065)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

HTML

404

Figures (1-3)

158

Sum=587

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

130

Download

236

Sum=366

Publishing Process of This Article

Item

Count

Browse

Download

Sum=79

Mar 24, 2025 (publication date) through Mar 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Mar 24, 2025; 16(3): 101766
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.101766

Full Size Figure Download Figure

Figure 3 Treatment regimen. qd: Per day.

Citation: Wei FF, Zhang J, Jia Z, Yao ZC, Chen CQ. Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report. World J Clin Oncol 2025; 16(3): 101766
URL: https://www.wjgnet.com/2218-4333/full/v16/i3/101766.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i3.101766